US regulators are stepping up scrutiny of cancer indications that were granted an accelerated approval on the basis of surrogate endpoints but that have failed to show clinical or survival benefits on more extensive testing. At issue are a number of cancer indications for immunotherapies. Four have already been withdrawn (voluntarily by the manufacturer), and […]
A large, retrospective study shows how germline genetic testing has evolved over time in women with breast or ovarian cancer and reveals a path forward for testing these patients. Investigators found racial and ethnic disparities in genetic testing as well as “persistent underuse” of testing in patients with ovarian cancer. The team also discovered that […]
